The team at GobyMeds is here to support you
Sexton and Denise Wootten for valuable advices
Care that grows with you, year after year Most patients move from assessment, to active optimization, to maintenance repeat labs, adjusted dosing, touch-ups, and wellness visits as life changes
These are the factors that typically point toward the slower path: Prior intolerable nausea or vomiting on semaglutide, tirzepatide, or other GLP-1 medications History of GERD, gastroparesis, or functional GI disorders Lower body weight, where the effective dose-per-kilogram is relatively higher at standard doses First-time users of peptide or GLP-class medications with no tolerability baseline The slow-titration approach does not change the target dose or the expected outcomes
BPC-157 (Body Protection Compound-157) is a synthetic peptide originally derived from a protective protein found in the stomach
, GLP-1 , GLP-1 GLP-1